Hormonal
Once-weekly subcutaneous semaglutide 2.4 mg, used as an adjunct to behavioral intervention, produces substantial and sustained weight loss (mean -15.2%) and improves cardiometabolic risk factors in adults with obesity or overweight with comorbidities over 104 weeks.
If you have obesity or overweight with a related health issue, adding once-weekly semaglutide 2.4 mg to your diet and exercise plan can help you lose about 15% of your body weight over two years. This is significantly more than diet and exercise alone. Expect some stomach issues like nausea at first, but they usually get better. You need to keep taking the medication to keep the weight off.
In summary, in adults with overweight (with at least one weight-related comorbidity) or obesity, semaglutide treatment led to substantial, sustained weight loss over 104 weeks versus placebo.
Why this rating
Phase 3, randomized, double-blind, placebo-controlled, multinational trial with a large sample size (n=304) and long duration (104 weeks).
Source
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
W. Timothy Garvey et al. · Nature Medicine · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →